Delving into the Latest Updates on T-cell-targeted peptide epitope vaccine (gold nanoparticle, Ebola virus infection)(Emergex) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

T-cell-targeted peptide epitope vaccine (gold nanoparticle, Marburgvirus infection), T-cell-targeted peptide epitope vaccine (microneedle patch/gold nanoparticle, Ebola virus/ Marburg virus infection)

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication-

Inactive Indication

Hemorrhagic Fever, EbolaMarburg Virus Disease

Originator Organization

Gylden Pharma Ltd.

Active Organization-

Inactive Organization

Gylden Pharma Ltd.

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

ABSTRACTA single blind, randomized, placebo-controlled, single-center phase I clinical trial of a CD8+T-cell peptide epitope vaccine against infectious mononucleosis was conducted with 14 HLA B*0801-positive, Epstein-Barr virus (EBV)-seronegative adults. The vaccine comprised the HLA B*0801-restricted peptide epitope FLRGRAYGL and tetanus toxoid formulated in a water-in-oil adjuvant, Montanide ISA 720. FLRGRAYGL-specific responses were detected in 8/9 peptide-vaccine recipients and 0/4 placebo vaccine recipients by gamma interferon enzyme-linked immunospot assay and/or limiting-dilution analysis. The same T-cell receptor Vβ CDR3 sequence that is found in FLRGRAYGL-specific T cells from most EBV-seropositive individuals could also be detected in the peripheral blood of vaccine recipients. The vaccine was well tolerated, with the main side effect being mild to moderate injection site reactions. After a 2- to 12-year follow-up, 1/2 placebo vaccinees who acquired EBV developed infectious mononucleosis, whereas 4/4 vaccinees who acquired EBV after completing peptide vaccination seroconverted asymptomatically. Single-epitope vaccination did not predispose individuals to disease, nor did it significantly influence development of a normal repertoire of EBV-specific CD8+T-cell responses following seroconversion.

100 Deals associated with T-cell-targeted peptide epitope vaccine (gold nanoparticle, Ebola virus infection)(Emergex)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemorrhagic Fever, Ebola	Preclinical	United Kingdom	Gylden Pharma Ltd.	05 Jan 2021
Marburg Virus Disease	Preclinical	United Kingdom	Gylden Pharma Ltd.	05 Jan 2021